Boston Scientific Long-Term Debt increased by 0.1% to $11.60B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.6%, from $10.89B to $11.60B. Over 4 years (FY 2020 to FY 2024), Long-Term Debt shows an upward trend with a 4.1% CAGR.
An increase indicates higher financial leverage, which can amplify returns on equity but also increases interest expense and financial risk.
Loans and financial obligations with a maturity period exceeding one year, typically consisting of corporate bonds and n...
Capital-intensive firms or those with aggressive share buyback programs often carry higher long-term debt than asset-light competitors.
long_term_debt| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.11B | $9.09B | $9.07B | $9.31B | $8.97B | $8.58B | $8.94B | $9.01B | $9.05B | $8.90B | $9.10B | $10.62B | $10.57B | $10.89B | $10.75B | $11.31B | $11.59B | $11.60B |
| QoQ Change | — | -0.3% | -0.2% | +2.6% | -3.6% | -4.3% | +4.1% | +0.8% | +0.5% | -1.7% | +2.3% | +16.7% | -0.5% | +3.0% | -1.3% | +5.2% | +2.5% | +0.1% |
| YoY Change | — | — | — | — | -1.5% | -5.5% | -1.4% | -3.2% | +0.9% | +3.7% | +1.9% | +17.9% | +16.8% | +22.3% | +18.1% | +6.5% | +9.6% | +6.6% |